zolmitriptan造句

• Examples include triptans such as zolmitriptan and ergot alkaloids such as methysergide.
• Variations of the drug are being developed including Zolmitriptan.
• Oral rizatriptan and nasal zolmitriptan are the most used triptans for migraines in children.
• The elimination of zolmitriptan is reduced by moclobemide and if the combination is used, a dosage reduction of zolmitriptan is recommended.
• The elimination of zolmitriptan is reduced by moclobemide and if the combination is used, a dosage reduction of zolmitriptan is recommended.
• Following administration of cimetidine, the half-life and AUC of zolmitriptan and its active metabolites were approximately doubled ( see CLINICAL PHARMACOLOGY in product pamphlet ).
• Now migraine patients also have three newer medications to choose from, all in tablet form : rizatriptan ( Maxalt ), zolmitriptan ( Zomig ) and naratriptan ( Amerge ).
• It is the newest member of a medications class known as the " triptan " drugs, and is closely related to sumatriptan ( Imitrex, which six years ago became the first major drug approved specifically for migraine ), naratriptan and zolmitriptan.
• Zolmitriptan is different from the other triptans because it is converted to an active N-desmethyl metabolite which has higher affinity for the 5-HT 1D and 5-HT 1B receptors; both substances have a biological half-life of 2 to 3 hours.
• Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension, should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide, and should not be administered to patients with hemiplegic or basilar migraine.
• "' Telcagepant "'( INN ) ( code name "'MK-0974 "') is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co . In the acute treatment of migraine, it was found to have equal potency to rizatriptan and zolmitriptan in two Phase III clinical trials.
• During his time as R & D Director, the organisation was responsible for the successful development of Zovirax ( anti-herpes ); Lamictal ( anti-epileptic ); Retrovir : AZT ( anti-HIVAIDS ); Acrivastine ( anti-histamine ); Atovaquone ( PCP / Malaria ); Exosurf ( infant respiratory distress ); Mivacron and Nuromax ( neuromuscular blockade ); Wellferon ( Hepatitis B & C ); Zolmitriptan ( anti migraine ); plus an extensive range of over-the-counter formulations; particularly products for coughs and colds ( Sudafed ), analgesia ( Calpol ) and skin care.